Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. diabetes patient
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Diabetes Patient Articles & Analysis

116 news found

Protheragen-ING Releases Hundreds of APIs: Anti-Tumor APIs, Hypoglycemic APIs, Antipsychotic APIs, Bronchiectasis APIs, Antihypertensive APIs

Protheragen-ING Releases Hundreds of APIs: Anti-Tumor APIs, Hypoglycemic APIs, Antipsychotic APIs, Bronchiectasis APIs, Antihypertensive APIs

Some of the anti-tumor APIs supplied by Protheragen-ING are: enzalutamide, olaparib, idelalisib, neratinib maleate, ixazomib citrate, bendamustine hydrochloride monohydrate, ponatinib HCL, dasatinib, lenalidomide, afatinib dimaleate, etc. Dedicated Solutions for Diabetes Management For diabetes, Protheragen-ING’s hypoglycemic APIs are the key to its cure. ...

ByProtheragen-ING


Vantage Welcomes Roczen!

Vantage Welcomes Roczen!

We are delighted to welcome Roczen to the community of healthcare organisations leveraging Vantage Software! We look forward to working together and helping them deliver exceptional care and support to those living with chronic conditions. Book a Free Demo ...

ByVantage Software


New data from pivotal studies with aflibercept 8 mg

New data from pivotal studies with aflibercept 8 mg

New subgroup and further analyses of the pivotal studies PULSAR, PHOTON and CANDELA will provide further insights into durability results of extended treatment intervals, patient characteristics as well as efficacy and safety of aflibercept 8 mg versus aflibercept 2 mg (EyleaTM) in patients with neovascular (wet) age-related macular degeneration (nAMD) and ...

ByBayer AG


Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes

Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes

“Patients with chronic kidney disease are faced with an increased risk of cardiovascular events,” said Professor Peter Rossing, Head of Complications Research at the Steno Diabetes Center Copenhagen. ...

ByBayer AG


Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)

Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)

TGen is part of City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. This precision medicine affiliation enables both institutes to complement each other in research and patient care, with City of Hope providing a significant clinical setting to advance scientific discoveries made by ...

ByNautilus Biotechnology


Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes

Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes

Addressing an alternative pathway, Kerendia offers protection as it selectively binds to the MR receptor, blocking harmful effects of MR overactivation. “Patients with chronic kidney disease and type 2 diabetes are three times more likely to die from a cardiovascular event than those with type 2 diabetes alone. ...

ByBayer AG


Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease

Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease

(“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD). ...

ByInversago Pharma


World Diabetes Day

World Diabetes Day

An estimated 415 million people are living with diabetes in the world. Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye ...

ByNeurovalens Limited


Apollo Medical Holdings, Inc. Receives NCQA`s HEDIS Health Plan Measure Certification for Measurement Year 2022

Apollo Medical Holdings, Inc. Receives NCQA`s HEDIS Health Plan Measure Certification for Measurement Year 2022

This year's certified measures include Hemoglobin A1c Control for Patients with Diabetes (HBD), Blood Pressure Control for Patients with Diabetes (BPD), Kidney Health Evaluation for Patients with Diabetes (KED), Lead Screening in Children (LSC), and Child and Adolescent Well-Care Visits (WCV). ...

ByApollo Medical Holdings, Inc.


XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAID

XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAID

Destiny Pharma is developing the novel formulation of XF-73 Dermal for the prevention of infections associated with open wounds and broken skin including diabetic foot ulcers (DFUs) – up to 25% of US diabetic patients may suffer from DFUs in their lifetime and c. 13% have active ulcers. ...

ByDestiny Pharma plc


New and Encouraging Global Diabetes Market Research Shows People with Diabetes are More Motivated to Manage their Condition than Healthcare Providers May Realize

New and Encouraging Global Diabetes Market Research Shows People with Diabetes are More Motivated to Manage their Condition than Healthcare Providers May Realize

Over half of patients surveyed agreed that they consistently follow their healthcare providers’ recommendations for managing their diabetes. ...

ByLifeScan


Detailed data from pivotal studies with aflibercept 8 mg demonstrate sustained improvements in visual acuity and anatomic measures with large majority of patients maintaining treatment intervals of 16 weeks at week 48

Detailed data from pivotal studies with aflibercept 8 mg demonstrate sustained improvements in visual acuity and anatomic measures with large majority of patients maintaining treatment intervals of 16 weeks at week 48

Patients were randomized in three different arms and all patients in the aflibercept 8 mg arms were continuously evaluated under stringent, clinically relevant, and patient focused dosing regimen modification (DRM) criteria. 77% of nAMD and 89% of DME patients maintained every 16-week dosing intervals with aflibercept 8 mg at ...

ByBayer AG


PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022

PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022

PMC-403 is a novel TIE2-activating antibody that stabilizes dysfunctional leaky disorganized pathological vessels. Wet AMD patients, who are suboptimal responding to Lucentis and Eylea, will be recruited for Phase I trial. PMC-402 is a TIE2-activating antibody that stabilizes dysfunctional leaky disorganized pathological vessels. Diabetic ...

ByPharmAbcine Inc.


Microbion Corporation Announces Data Highlighting Pravibismane’s Effect on Bacterial Energetics Presented at ASM Microbe 2022

Microbion Corporation Announces Data Highlighting Pravibismane’s Effect on Bacterial Energetics Presented at ASM Microbe 2022

Pravibismane has also demonstrated safety in multiple clinical studies including treatment of patients with diabetic foot infections and patients with serious orthopedic device-related infections. ...

ByMicrobion Corporation


What is CO2 Fractional Laser Treatment

What is CO2 Fractional Laser Treatment

Avoid thermal damage Fractional carbon dioxide laser treatment can effectively avoid side effects such as thermal damage, and at the same time can promote the healing of the skin, making up for the lack of treatment technology that takes a long time in the recovery period, taking care of the specific requirements of each patient, suitable for all kinds of wrinkles , including ...

ByBvlaser Bestview Medical and Beauty Equipment Co., Ltd


All patients in DiagnodE-B have received an additional (booster) injection of Diamyd

All patients in DiagnodE-B have received an additional (booster) injection of Diamyd

The last patient in the investigator-initiated clinical trial DIAGNODE-B has received its additional injection (“booster”) of the therapeutic diabetes vaccine Diamyd®. The trial includes 6 patients with Type 1 diabetes who earlier participated in the DIAGNODE-1 or DIAGNODE-2 trials and who carry the genetic HLA ...

ByDiamyd Medical AB


Bayer to present new cardiorenal data for Kerendia (finerenone) across a broad range of patients with early to late-stage chronic kidney disease and type 2 diabetes

Bayer to present new cardiorenal data for Kerendia (finerenone) across a broad range of patients with early to late-stage chronic kidney disease and type 2 diabetes

Despite well-controlled blood glucose levels and blood pressure, many patients with CKD and diabetes still progress to loss of kidney function. ...

ByBayer AG


Updated results from clinical trial with Diamyd presented today at diabetes conference

Updated results from clinical trial with Diamyd presented today at diabetes conference

Diamyd Medical is represented with its own booth in the Exhibitor Hall at the EASD conference which is held this week in Stockholm, September 19-23, to promote the ongoing confirmatory Phase III trial DIAGNODE-3 in recent-onset Type 1 diabetes patients positive for HLA DR3-DQ2. About the GADinLADA trial The main aim of the trial was to evaluate the safety of ...

ByDiamyd Medical AB


Kerendia (finerenone) receives updated label in the U.S. to include findings from Phase III FIGARO-DKD cardiovascular outcomes study

Kerendia (finerenone) receives updated label in the U.S. to include findings from Phase III FIGARO-DKD cardiovascular outcomes study

Patients living with chronic kidney disease associated with type 2 diabetes are three times more likely to die from a cardiovascular event than those with type 2 diabetes alone. ...

ByBayer AG


Medis QFR continues to show superiority over standard angiography, after a FU-period of 2 years

Medis QFR continues to show superiority over standard angiography, after a FU-period of 2 years

In the September 2022 issue of JACC journals (https://www.jacc.org/doi/10.1016/j.jacc.2022.06.044), the FAVOR III China Study Group published a sub-study that was aimed to ascertain whether the beneficial outcomes of QFR® guidance for lesion selection during PCI is affected by diabetes status. From the total of 3825 patients enrolled, 1295 (33.9%) had ...

ByMedis Medical Imaging Systems B.V.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT